Femasys Inc. (FEMY) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 8 wins, 4 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseFEMY / S&P -50.24% / 15.20% |
WinFEMY / S&P 21.86% / 15.00% |
LoseFEMY / S&P -62.89% / 50.40% |
| 2026-Q12/3 |
LoseFEMY / S&P -27.08% / -4.33% |
WinFEMY / S&P 39.88% / 11.30% |
WinFEMY / S&P 261.54% / 27.70% |
| 2025-Q43/3 |
WinFEMY / S&P 63.64% / 2.65% |
WinFEMY / S&P 40.77% / 9.00% |
WinFEMY / S&P 314.12% / 13.40% |
| 2025-Q32/3 |
LoseFEMY / S&P -63.56% / 8.12% |
WinFEMY / S&P 63.53% / 4.61% |
WinFEMY / S&P 361.73% / 13.45% |
| 2025-Q22/3 |
LoseFEMY / S&P -22.72% / 10.94% |
WinFEMY / S&P 98.61% / 4.83% |
WinFEMY / S&P 367.47% / 10.63% |
| 2025-Q12/3 |
WinFEMY / S&P 13.64% / -4.27% |
WinFEMY / S&P 61.97% / 4.98% |
LoseFEMY / S&P 8.33% / 10.57% |
| 2024-Q41/3 |
LoseFEMY / S&P -0.90% / 2.41% |
WinFEMY / S&P 51.97% / 5.25% |
LoseFEMY / S&P -7.61% / 6.15% |
| 2024-Q31/3 |
LoseFEMY / S&P -2.63% / 5.89% |
WinFEMY / S&P 15.33% / 5.89% |
LoseFEMY / S&P -16.49% / 6.11% |
| 2024-Q20/3 |
LoseFEMY / S&P -26.45% / 4.28% |
LoseFEMY / S&P -20.57% / 5.38% |
LoseFEMY / S&P -13.54% / 5.12% |
| 2024-Q11/3 |
WinFEMY / S&P 58.97% / 10.56% |
LoseFEMY / S&P -11.00% / 5.71% |
LoseFEMY / S&P -12.50% / 5.59% |
| 2023-Q40/3 |
LoseFEMY / S&P -67.28% / 11.69% |
LoseFEMY / S&P -11.13% / 6.81% |
LoseFEMY / S&P -3.16% / 7.78% |
| 2023-Q32/3 |
WinFEMY / S&P 484.31% / -3.27% |
LoseFEMY / S&P -10.86% / 7.52% |
WinFEMY / S&P 22.78% / -5.03% |
| 2023-Q21/3 |
LoseFEMY / S&P -53.00% / 8.74% |
LoseFEMY / S&P 4.16% / 9.50% |
WinFEMY / S&P 31.51% / -8.57% |
| 2023-Q12/3 |
WinFEMY / S&P 20.56% / 7.50% |
LoseFEMY / S&P 0.64% / 10.77% |
WinFEMY / S&P -6.80% / -15.69% |
| 2022-Q40/3 |
LoseFEMY / S&P -20.35% / 7.56% |
LoseFEMY / S&P 2.25% / 11.88% |
LoseFEMY / S&P -63.88% / -17.99% |
| 2022-Q30/3 |
LoseFEMY / S&P -53.11% / -4.88% |
LoseFEMY / S&P 1.66% / 13.47% |
LoseFEMY / S&P -81.41% / -1.41% |
| 2022-Q21/3 |
WinFEMY / S&P 6.64% / -16.10% |
LoseFEMY / S&P -8.12% / 13.71% |
LoseFEMY / S&P -87.19% / 11.04% |
| 2022-Q10/3 |
LoseFEMY / S&P -42.05% / -4.60% |
LoseFEMY / S&P 5.79% / 15.97% |
LoseFEMY / S&P -84.70% / 42.23% |
| 2021-Q40/3 |
LoseFEMY / S&P -43.40% / 11.03% |
LoseFEMY / S&P FEMY unavailable / 15.00% |
LoseFEMY / S&P FEMY unavailable / 96.40% |
| 2021-Q30/3 |
LoseFEMY / S&P -15.04% / 0.58% |
LoseFEMY / S&P FEMY unavailable / 10.77% |
LoseFEMY / S&P FEMY unavailable / 69.42% |
| 2021-Q20/3 |
LoseFEMY / S&P FEMY unavailable / 8.55% |
LoseFEMY / S&P FEMY unavailable / 6.58% |
LoseFEMY / S&P FEMY unavailable / 51.81% |
| 2021-Q10/3 |
LoseFEMY / S&P FEMY unavailable / 6.17% |
LoseFEMY / S&P FEMY unavailable / -1.06% |
LoseFEMY / S&P FEMY unavailable / 7.39% |
| 2020-Q40/3 |
LoseFEMY / S&P FEMY unavailable / 12.15% |
LoseFEMY / S&P FEMY unavailable / -3.72% |
LoseFEMY / S&P FEMY unavailable / -33.42% |
| 2020-Q30/3 |
LoseFEMY / S&P FEMY unavailable / 8.93% |
LoseFEMY / S&P FEMY unavailable / -2.04% |
LoseFEMY / S&P FEMY unavailable / -27.10% |
| 2020-Q20/3 |
LoseFEMY / S&P FEMY unavailable / 20.54% |
LoseFEMY / S&P FEMY unavailable / -0.46% |
LoseFEMY / S&P FEMY unavailable / -27.11% |
| 2020-Q10/3 |
LoseFEMY / S&P FEMY unavailable / -19.60% |
LoseFEMY / S&P FEMY unavailable / 3.47% |
LoseFEMY / S&P FEMY unavailable / -14.75% |
| 2019-Q40/3 |
LoseFEMY / S&P FEMY unavailable / 9.07% |
LoseFEMY / S&P FEMY unavailable / 5.36% |
LoseFEMY / S&P FEMY unavailable / 2.99% |
| 2019-Q30/3 |
LoseFEMY / S&P FEMY unavailable / 1.70% |
LoseFEMY / S&P FEMY unavailable / 5.02% |
LoseFEMY / S&P FEMY unavailable / 0.21% |
| 2019-Q20/3 |
LoseFEMY / S&P FEMY unavailable / 4.30% |
LoseFEMY / S&P FEMY unavailable / 6.64% |
LoseFEMY / S&P FEMY unavailable / 8.65% |
| 2019-Q10/3 |
LoseFEMY / S&P FEMY unavailable / 13.65% |
LoseFEMY / S&P FEMY unavailable / 8.12% |
LoseFEMY / S&P FEMY unavailable / 14.29% |
| 2018-Q40/3 |
LoseFEMY / S&P FEMY unavailable / -13.52% |
LoseFEMY / S&P FEMY unavailable / 9.05% |
LoseFEMY / S&P FEMY unavailable / 18.23% |
| 2018-Q30/3 |
LoseFEMY / S&P FEMY unavailable / 7.71% |
LoseFEMY / S&P FEMY unavailable / 10.21% |
LoseFEMY / S&P FEMY unavailable / 19.06% |
| 2018-Q20/3 |
LoseFEMY / S&P FEMY unavailable / 3.43% |
LoseFEMY / S&P FEMY unavailable / 9.03% |
LoseFEMY / S&P FEMY unavailable / 14.46% |
| 2018-Q10/3 |
LoseFEMY / S&P FEMY unavailable / -0.76% |
LoseFEMY / S&P FEMY unavailable / 7.68% |
LoseFEMY / S&P FEMY unavailable / 12.46% |
| 2017-Q40/3 |
LoseFEMY / S&P FEMY unavailable / 6.64% |
LoseFEMY / S&P FEMY unavailable / 7.03% |
LoseFEMY / S&P FEMY unavailable / 13.82% |
| 2017-Q30/3 |
LoseFEMY / S&P FEMY unavailable / 4.48% |
LoseFEMY / S&P FEMY unavailable / 5.68% |
LoseFEMY / S&P FEMY unavailable / 17.57% |
| 2017-Q20/3 |
LoseFEMY / S&P FEMY unavailable / 3.09% |
LoseFEMY / S&P FEMY unavailable / 4.83% |
LoseFEMY / S&P FEMY unavailable / 17.74% |
| 2017-Q10/3 |
LoseFEMY / S&P FEMY unavailable / 6.07% |
LoseFEMY / S&P FEMY unavailable / 3.67% |
LoseFEMY / S&P FEMY unavailable / 13.32% |
| 2016-Q40/3 |
LoseFEMY / S&P FEMY unavailable / 3.82% |
LoseFEMY / S&P FEMY unavailable / 2.09% |
LoseFEMY / S&P FEMY unavailable / 7.05% |
| 2016-Q30/3 |
LoseFEMY / S&P FEMY unavailable / 3.85% |
LoseFEMY / S&P FEMY unavailable / 0.20% |
LoseFEMY / S&P FEMY unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | FEMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -60.70% | 20.78% |
| Annualized return | -60.70% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | FEMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.24% | 83.14% |
| Annualized return | -55.42% | 12.86% |
10Y · 2021-06-18 to 2026-08-27
| Metric | FEMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.84% | 319.30% |
| Annualized return | -35.95% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RETRACTABLE TECHNOLOGIES INC (RVP) | United States | $0.021B | -6.44 |
| HeartBeam, Inc. (BEAT) | United States | $0.022B | -2.08 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |